Changes in renal function in patients with atrial fibrillation: An analysis from the RE-LY trial

Journal of the American College of Cardiology

Volumn 65, Issue 23, 2015, Pages 2481-2493

  Böhm, Michael ^a   Ezekowitz, Michael D ^b,c   Connolly, Stuart J ^d   Eikelboom, John W ^d   Hohnloser, Stefan H ^e   Reilly, Paul A ^f   Schumacher, Helmut ^g   Brueckmann, Martina ^g,h   Schirmer, Stephan H ^a   Kratz, Mario T ^a   Yusuf, Salim ^d   Diener, Hans Christoph ⁱ   Hijazi, Ziad ^j   Wallentin, Lars ^j  

^a SAARLAND UNIVERSITY   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e GOETHE UNIVERSITY   (Germany)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

anticoagulation; atrial fibrillation; renal function; thrombin inhibition; vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DABIGATRAN ETEXILATE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOPROTEIN P INHIBITOR; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; VASODILATOR AGENT; VITAMIN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN; PYRIDINE DERIVATIVE;

AGED; ATRIAL FIBRILLATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DRUG EFFECTS; KIDNEY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SINGLE BLIND PROCEDURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; DABIGATRAN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PYRIDINES; RISK FACTORS; SINGLE-BLIND METHOD; WARFARIN;

EID: 84930692288     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.577     Document Type: Article

References (35)

1. M.L. Chatrou, K. Winckers, T.M. Hackeng, C.P. Reutelingsperger, and L.J. Schurgers Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists Blood Rev 26 2012 155 166
2. G. Luo, P. Ducy, and M.D. McKee Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein Nature 386 1997 78 81
3. H.M. Spronk, B.A. Soute, L.J. Schurgers, H.H. Thijssen, J.G. De Mey, and C. Vermeer Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats J Vasc Res 40 2003 531 537
4. L.J. Schurgers, H.M. Spronk, B.A. Soute, P.M. Schiffers, J.G. DeMey, and C. Vermeer Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats Blood 109 2007 2823 2831
5. L.J. Schurgers, I.A. Joosen, and E.M. Laufer Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype PLoS One 7 2012 e43229
6. J.B. Cannata-Andía, M. Rodríguez-García, N. Carrillo-López, M. Naves-Díaz, and B. Díaz-López Vascular calcifications: pathogenesis, management, and impact on clinical outcomes J Am Soc Nephrol 17 Suppl 3 2006 S267 S273
7. R.M. Holden, A.R. Morton, J.S. Garland, A. Pavlov, A.G. Day, and S.L. Booth Vitamins K and D status in stages 3-5 chronic kidney disease Clin J Am Soc Nephrol 5 2010 590 597
8. I.O. Lee, M.T. Kratz, S.H. Schirmer, M. Baumhäkel, and M. Böhm The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice J Pharmacol Exp Ther 343 2012 253 257
9. F. Bea, J. Kreuzer, M. Preusch, and S. Schaab Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 26 2006 2787 2792
10. M.D. Ezekowitz, S. Connolly, and A. Parekh Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 2009 805 810
11. S.J. Connolly, M.D. Ezekowitz, S. Yusuf for the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
12. A.S. Levey, L.A. Stevens, C.H. Schmid for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
13. A.S. Levey, J. Coresh, T. Greene for the Chronic Kidney Disease Epidemiology Collaboration Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values Clin Chem 53 2007 766 772
14. C.H. Mallinckrodt, P.W. Lane, D. Schnell, Y. Peng, and J.P. Mancuso Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials Drug Information J 42 2008 303 319
15. J.A. Lopes, and S. Jorge The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review Clin Kidney J 6 2013 8 14
16. H.J. Lambers Heerspink, H. Tighiouart, and Y. Sang GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials Am J Kidney Dis 64 2014 860 866
17. L.A. Inker, H.J. Lambers Heerspink, and H. Mondal GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials Am J Kidney Dis 64 2014 848 859
18. B.R. Hemmelgarn, J. Zhang, and B.J. Manns Progression of kidney dysfunction in the community-dwelling elderly Kidney Int 69 2006 2155 2161
19. W. Ananthapanyasut, S. Napan, and E.H. Rudolph Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease Clin J Am Soc Nephrol 5 2010 173 181
20. U. Baber, V.J. Howard, and J.L. Halperin Association of chronic kidney disease with atrial fibrillation among adults in the United States: reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Circ Arrhythm Electrophysiol 4 2011 26 32
21. R. Deo, R. Katz, and B. Kestenbaum Impaired kidney function and atrial fibrillation in elderly subjects J Card Fail 16 2010 55 60
22. K.A. Fox, J.P. Piccini, and D. Wojdyla Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment Eur Heart J 32 2011 2387 2394
23. A.S. Go, M.C. Fang, N. Udaltsova for the ATRIA Study Investigators Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Circulation 119 2009 1363 1369
24. S.H. Hohnloser, Z. Hijazi, and L. Thomas Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
25. L. Li, A. Chang, and S.G. Rostand A within-patient analysis for time-varying risk factors of CKD progression J Am Soc Nephrol 25 2014 606 613
26. E.L. Schiffrin, M.L. Lipman, and J.F. Mann Chronic kidney disease: effects on the cardiovascular system Circulation 116 2007 85 97
27. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
28. S.V. Brodsky, T. Nadasdy, and B.H. Rovin Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate Kidney Int 80 2011 181 189
29. K. Ware, P. Brodsky, and A.A. Satoskar Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation J Am Soc Nephrol 22 2011 1856 1862
30. A. Ozcan, K. Ware, and E. Calomeni 5/6 Nephrectomy as a validated rat model mimicking human warfarin-related nephropathy Am J Nephrol 35 2012 356 364
31. S.V. Brodsky, M. Collins, and E. Park Warfarin therapy that results in an international normalization ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease Nephron Clin Pract 115 2010 c142 c146
32. E.M. Sparkenbaugh, P. Chantrathammachart, and J. Mickelson Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease Blood 123 2014 1747 1756
33. Z. Hijazi, S.H. Hohnloser, and J. Oldgren Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation 129 2014 961 970
34. Z. Harel, M. Sholzberg, and P.S. Shah Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD J Am Soc Nephrol 25 2014 431 442
35. J. Kornej, G. Hindricks, and A. Banerjee Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2 and CHA2DS2-VASc scores and arrhythmia recurrences Heart 101 2015 126 131